Introduction {#Sec1}
============

The frequency of invasive fungal diseases (IFD) has increased dramatically within the last few years mainly because of the growing number of immunocompromised patients \[[@CR1]\]. *Candida* sp. and *Aspergillus* sp. are the main pathogenic fungal agents that may lead to severe infectious complications particularly in neutropenic patients, recipients of allogeneic hematopoietic stem cells transplants (HSCT), or solid organ transplants, as well as patients in intensive care units presenting with multiple risk factors (e.g., broad-spectrum antibiotics, intravascular catheters, kidney failure, dialysis, long-term intubation) \[[@CR2], [@CR3]\]. In addition, the mortality rate associated with IFD remains very high (≥ 40%) \[[@CR4]\].

IFDs are difficult to diagnose and treat although various clinical guidelines have been published in the US by the Infectious Diseases Society of America \[[@CR5]\], in Europe by the European Conference on Infections in Leukaemia (ECIL) \[[@CR6]\] and the European Society of Clinical Microbiology and Infectious Diseases \[[@CR7]\], and in various countries \[[@CR8]--[@CR12]\] to help physicians in their practices.

Antifungal drugs are used according to four different approaches: (1) prophylaxis for patients with a high risk of developing an IFD but without apparent symptoms \[[@CR13]--[@CR16]\]; (2) empiric treatment for patients with suspected fungal infection in the absence of radiologic, microbiologic, histologic, or serologic evidence, which is a widely used strategy for neutropenic patients with persistent fever after 4--7 days under broad-spectrum antibiotics or who become febrile after a period of apyrexia \[[@CR17], [@CR18]\]; (3) preemptive (also called diagnostic-driven) treatment where there is a high suspicion of IFD in high-risk patients with some radioclinical or biomarker evidence \[[@CR19]\], including possible IFD, according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria \[[@CR20]\]; or (4) curative treatment for probable or proven IFD according to the EORTC/MSG criteria \[[@CR20]\].

Within a context where both treatments and guidelines are fast evolving, this cross-sectional observational study aims to shed new light on IFD management in pediatric and adult hematologic units in France, describing the frequency of systemic antifungal prophylaxis, the characteristics of patients receiving antifungal prophylaxis, and the prescription practices used in clinical practice.

Methods {#Sec2}
=======

Study Design and Patients {#Sec3}
-------------------------

This was an observational, cross-sectional study carried out over 5 consecutive days in 2013. Although major changes in practices occurred when the empirical strategy emerged in the 2000s and then anti-filamentous chemoprophylaxis in 2007, we consider that practices changed only slightly between 2013 and 2018 and therefore this does not invalidate our observations. French hematologic units located in university hospital and medical cancer centers were invited to participate. All patients (children or adults) with hematologic malignancy hospitalized in participating hematologic units during the 5-day observational period and who gave their written informed consent were included in the study. No other selection criterion was applied. Each center participated in the study over 5 consecutive days, but due to organizational considerations, centers did not all participate in the study within the same period, and patient recruitment was spread over a period of 6 weeks.

Data Source {#Sec4}
-----------

Data were entered by investigators or their staff on electronic case report forms (eCRFs), including antifungal strategies at inclusion, hospitalization conditions, IFD history, hematologic malignancy and underlying conditions, antifungal treatments and other ongoing treatments, and IFD classification established by the physician. Clinical signs, imaging, and other examinations related to IFD episodes were collected for the patients who received preemptive or curative treatment. All data were recorded through a secure online case report form.

### Compliance with Ethics Guidelines {#Sec5}

The data were anonymized before any analysis occurred. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study. According to French regulatory requirements, approvals from the French review boards (Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé and Commission Nationale de l'Informatique et des Libertés) were obtained.

Statistical Analyses {#Sec6}
--------------------

The statistical analyses performed were mainly descriptive. The variables were analyzed according to the following general rules: quantitative variables were described by the number of available and missing data, mean, standard deviation, first quartile, median, third quartile, and minimum and maximum; qualitative and ordinal variables were described by the number of available and missing data, frequency, and percentage (of the total number of values available) of each modality. Confidence intervals (CIs) at 95% were calculated according to Wilson's method (with continuity correction). Subgroup analyses were performed according to the last systemic antifungal therapeutic strategy reported for patients treated at least 1 day during the 5 observation days. Antifungal prophylaxis was also described as primary (i.e., in the absence of a history of IFD) or secondary prophylaxis (in patients with a history of an IFD). A logistic regression model was used to determine the factors impacting the treatment with antifungal drugs. Multivariate analysis was preceded by univariate analysis; significant factor at the threshold of the univariate analysis was then introduced. It was based on conventional univariate statistical tests: distributions of qualitative variables were compared using the *χ*^2^ test or Fisher's exact test if the expected frequency in any of the cells of the contingency table was less than five. A stepwise selection method (forward and backward combination of methods) was used to automatically select the most appropriate factors to take the model factors into account.

All analyses were carried out using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

Participating Centers {#Sec8}
---------------------

Of the 31 French hematologic centers that initially agreed to participate in the study, 24 contributed patients. These active units had a total of 717 beds including 368 rooms with air treatment.

Twenty-two units were in university hospitals, and the two others were in medical cancer centers. Sixteen units were adult, and eight were pediatric. Two units were exclusively adult HSCT units.

Patients {#Sec9}
--------

Four hundred ninety-four patients were enrolled in the study between 16 September 2013 and 25 October 2013.

Most patients (87%) were adults, 288 (58%) suffered from acute leukemia, and 41 (8%) and 147 (30%) were recipients of autologous or allogeneic HSCT, respectively. Among those who received an allogeneic HSCT, 123 (84%) had recently been allo-transplanted (for less than 6 months). Thirty-seven percent of the patients were in relapse or refractory phase, and 231 (47%) were in partial or complete remission. Neutropenia was present for at least 10 days in 127 patients (26%), and 50 patients (10%) had a persistent fever refractory to antibiotic therapy. Three hundred forty-six patients (70%) had been hospitalized in the unit for less than 15 days. A total of 313 patients (63%) entered a room with air treatment, most of them (89%) since their first day of entry in the unit: 172 patients (55%) were placed in a laminar air flow room or Immunair™ bed, 88 patients (28%) in a highly purified HEPA-filtered room, and 53 (17%) in a conventional room with Plasmair™ or the equivalent. Thirteen percent of the patients had already experienced an IFD episode.

These 494 patients were classified into four groups: group 1 included the allogeneic HSCT recipients (*n *= 147), group 2 included patients suffering from acute myeloblastic leukemia (AML) or myelodysplastic syndrome (MDS) (*n *= 131), group 3 included patients suffering from acute lymphoblastic leukemia (ALL) (*n *= 71), and group 4 included all patients not included in groups 1, 2, or 3 (*n *= 145). Their characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of patients according to the pathology profileGroup 1 *n *= 147Group 2 *n *= 131Group 3 *n *= 71Group 4 *n *= 145Total *n *= 494Gender (male)79 (54)83 (63)36 (51)89 (61)287 (58)Adults1\[35 (92)\]117 (89)44 (62)134 (92)430 (87)Age, years, median Adult (range)51.0 (21--71)58.0 (23--86)39.8 (18--70)64.6 (24--90)56.8 (18--90) Children (range)6.3 (0--12)8.9 (1--17)10.5 (1--17)8.8 (0--16)8.4 (0--17)Hematologic malignancy Acute myeloid leukemia67 (46)125 (95)192 (39) Myelodysplastic syndrome8 (5)6 (5)14 (3) Acute lymphoblastic leukemia25 (17)71 (100)96 (19) Hodgkin lymphoma13 (9)13 (9)26 (5) Non-Hodgkin lymphoma11 (7)83 (57)94 (19) Chronic lymphoid leukemia1 (1)11 (8)12 (2) Myeloma9 (6)32 (22)41 (8) Chronic myeloid leukemia6 (4)6 (1) Other7 (5)6 (4)13 (3)Disease status (relapse or refractory)92 (64)17 (13)12 (17)60 (41)181 (37)Underlying conditions Autologous transplant01 (1)2 (3)38 (26)41 (8) Allogeneic transplant^a^147 (100)147 (30) GVHD^b,c^47 (32)47 (32)  Grade I--II acute GVHD2323  Grade III--IV acute GVHD1818  Chronic GVHD1313 Neutropenic phase^c^64 (44)64 (44) ANC \< 0.5, 10/l for at least 10 days35 (24)62 (47)20 (28)10 (7)127 (26) Persistent fever refractory to antibiotic therapy15 (10)20 (15)5 (7)10 (7)50 (10) Previous IFD33 (22)17 (13)9 (13)3 (2)62 (13)Ongoing treatments Chemotherapy63 (43)106 (81)60 (85)98 (68)327 (66) Antibiotics125 (85)104 (79)48 (68)92 (63)369 (75) Immunosuppressors102 (69)10 (8)22 (31)27 (19)161 (33) Antivirals130 (88)73 (56)33 (47)79 (54)315 (64)Time since entry in the unit ≥ 30 days37 (25)19 (15)8 (11)7 (5)71 (14) Between 15 and 29 days25 (17)32 (24)11 (15)9 (6)77 (16) \< 15 days85 (58)80 (61)52 (73)129 (89)346 (70)Hospitalization in room with air treatment127 (86)99 (76)39 (55)48 (33)313 (63) Laminar air flow room or Immunair™ bed^d^96 (76)48 (49)18 (46)10 (21)172 (55) Highly purified HEPA-filtered room^d^24 (19)31 (31)11 (28)22 (46)88 (28) Conventional room with plasmair™ or equivalent^d^7 (5)20 (20)10 (26)16 (33)53 (17)Data are *n* (%), unless otherwise specified*ANC* absolute neutrophil count, *GVHD* graft-versus-host disease, *IFD* invasive fungal disease^a^123 patients transplanted for less than 6 months^b^Chronic and/or acute GVHD^c^Percentage among recipients of allogeneic hematopoietic stem cell transplant^d^Percentage among patients hospitalized in a room with air treatment

The demographic characteristics of the patients belonging to groups 1, 2, and 4 were similar. Because the patients from group 3 presented with ALL, this group included more children than the other groups (48%), and the median age of adult patients was lower (39.8 years in group 3 versus 51.0, 58.0, and 64.6 years in groups 1, 2, and 4, respectively). Regarding ongoing treatments, patients from group 1 were more likely to be treated with antibiotics (85%), antiviral agents (88%), and immunosuppressive treatments (69%). Moreover, they were more often placed in a sterile room, a laminar air flow room, Immunair™ bed, or highly purified HEPA-filtered room (82% vs. 60, 41, and 22% for groups 2, 3, and 4, respectively).

Regarding the 64 (13%) pediatric patients enrolled in the study, they had mean age of 8.4 years and were mainly suffering from ALL \[32 patients (50%)\] or AML \[20 patients (31%)\]. Less than 20% (12 patients) were HSCT recipients. Nineteen percent of the patients were in the relapse or refractory phase, and 38 (59%) were in partial or complete remission. Neutropenia was present for at least 10 days in 17 patients (27%), and 6 patients (9%) had a persistent fever refractory to antibiotic therapy. Their characteristics are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Main patient's characteristics and systemic antifungal strategy according to age groupAdults\
*n *=430Pediatrics\
*n *=64Total\
*N *=494Patient's characteristics Hematologic malignancy  Acute myeloid leukemia172 (40)20 (31)192 (39)  Myelodysplastic syndrome14 (3)14 (3)  Acute lymphoblastic leukemia64 (15)32 (50)96 (19)  Hodgkin lymphoma24 (6)2 (3)26 (5)  Non-Hodgkin lymphoma85 (20)9 (14)94 (19)  Chronic lymphoid leukemia12 (3)12 (2)  Myeloma41 (10)41 (8)  Chronic myeloid leukemia5 (1)1 (2)6 (1)  Other13 (3)13 (3) Disease status (relapse or refractory)169 (39)12 (19)181 (37) Underlying conditions  Autologous transplant41 (10)41 (8)  Allogeneic transplant^a^135 (31)12 (19)147 (30)  Acute GVHD^b^35 (26)6 (50)41 (28)  Neutropenia for at least 10 days110 (26)17 (26)127 (26)  Persistent fever refractory to antibiotic therapy44 (10)6 (9)50 (10)  Previous IFD57 (13)5 (8)62 (13) Ongoing treatments  Chemotherapy272 (63)55 (86)327 (66)  Antibiotics326 (76)43 (67)369 (75)  Immunosuppressors136 (32)25 (39)161 (33)  Antivirals303 (70)12 (19)315 (64) Time since entry in the unit  ≥ 30 days62 (14)9 (14)71 (14)  Between 15 and 29 days63 (15)14 (22)77 (16)  \< 15 days305 (71)41 (64)346 (70) Hospitalization in room with air treatment281 (65)32 (50)313 (63)  Laminar air flow room or Immunair™ bed^c^149 (53)23 (72)172 (55)  Highly purified HEPA-filtered room^c^79 (28)9 (28)88 (28)  Conventional room with Plasmair™ or equivalent^c^53 (19)53 (17)Systemic antifungal strategy Not treated with systemic antifungals204 (47)44 (69)248 (50) Treated with systemic antifungals226 (53)20 (31)246 (50)  Prophylactic strategy^d^174 (77)13 (65)187 (76)   Primary^*e*^135 (78)10 (77)145 (78)   Secondary^*e*^39 (22)3 (23)42 (22)  Empiric strategy^d^20 (9)5 (25)25 (10)  Preemptive or curative strategy^d^32 (14)2 (10)34 (14)Data are *n* (%), unless otherwise specified*GVHD* graft-versus-host disease, *IFD* invasive fungal disease^a^123 patients (114 adults and 9 pediatric patients) transplanted for less than 6 months^b^Percentage of recipients receiving allogeneic hematopoietic stem cell transplant^c^Percentage of patients hospitalized in room with air treatment^d^Percentage of patients treated with systemic antifungals^e^Percentage of patients receiving a systemic antifungal prophylactic strategy

Antifungal Strategies {#Sec10}
---------------------

The frequency of antifungal treatment was 50% (95% CI 45.3--54.3), i.e., 246 patients received a systemic antifungal treatment (as a prophylactic, empiric, preemptive, or curative strategy) during at least 1 of the 5-day observational periods.

The frequency of antifungal strategies is presented in Table [3](#Tab3){ref-type="table"} for each of the four groups. One hundred eighty-seven (38%) patients received antifungal prophylaxis, representing 76% of treated patients. The proportions of patients who received antifungal prophylaxis among those treated with antifungal agents were similar in the four groups: 80% in group 1, 72% in group 2, 63% in group 3, and 80% in group 4. Primary antifungal prophylaxis was delivered to 145 patients (78% of the patients who received antifungal prophylaxis), and the remaining 42 patients received secondary antifungal prophylaxis. The frequency of secondary prophylaxis was higher in group 4 than in the other groups.Table 3Frequency of systemic antifungal strategies according to the pathology profileGroup 1\
*n *= 147Group 2\
*n *= 131Group 3\
*n *= 71Group 4\
*n *= 145Total\
*n *= 494Not treated with systemic antifungals28 (19)53 (40)52 (73)115 (79)248 (50)Treated with systemic antifungals119 (81)78 (60)19 (27)30 (21)246 (50) Prophylactic strategy^a^95 (80)56 (72)12 (63)24 (80)187 (76)  Primary^b^75 (79)48 (86)10 (83)12 (50)145 (78)  Secondary^b^20 (21)8 (14)2 (17)12 (50)42 (22) Empiric strategy^a^13 (11)6 (8)2 (11)4 (13)25 (10) Preemptive or curative strategy^a^11 (9)16 (20)5 (26)2 (7)34 (14)Data are *n* (%)^a^Percentage among patients treated with systemic antifungals^b^Percentage among patients receiving a systemic antifungal prophylactic strategy

The frequency of antifungal strategies according to age group (i.e., adults and pediatrics) is presented in Table [2](#Tab2){ref-type="table"}. Of the 64 pediatric patients included in the study, 20 (31%) were treated with systemic antifungals; 13 received antifungal prophylaxis (mainly primary prophylaxis; 10 patients), representing 65% of treated patients.

Characteristics of Patients Receiving Antifungal Prophylaxis {#Sec11}
------------------------------------------------------------

Characteristics of the 187 patients who received antifungal prophylaxis are summarized in Table [4](#Tab4){ref-type="table"}. Half of the patients from groups 2 and 3 (patients with AML, ALL, or MDS) presented with neutropenia for at least 10 days when enrolled in the study compared with 17% for groups 1 and 4. Of the 95 patients treated with antifungal prophylaxis who had received allogeneic HSCT, 40% were in a neutropenic phase, 10% had developed acute grade I--II graft-versus-host disease (GVHD), 15% had acute grade III--IV GVHD, and 7% presented with chronic GVHD. One hundred fifty-seven patients were placed in a room with air treatment, with a similar proportion in each of the four groups. However, of the 88% of patients in a room with sterile air treatment (in the laminar air flow room, Immunair™ bed, or highly purified HEPA-filtered room), there were proportionately more patients from group 1 than in the other groups. Nineteen patients who received antifungal prophylaxis did not enter a sterile room, but were only placed in a conventional room with Plasmair™ or the equivalent.Table 4Characteristics of hospitalized patients receiving systemic antifungal prophylaxis according to the pathology profileGroup 1\
*n *= 95Group 2\
*n *= 56Group 3\
*n *= 12Group 4\
*n *= 24Total\
*n *= 187Gender (male)56 (59)32 (57)10 (83)14 (58)112 (60)Adults88 (93)53 (95)10 (83)23 (96)174 (93)Age, year, median Adult (range)52.2 (21--71)54.0 (23--81)34.9 (21--67)55.2 (24--67)52.7 (21--81) Children (range)7.7 (0--12)10.8 (10--14)6.9 (3--11)0.5 (NA)7.9 (0--14)Hematologic malignancy Acute myeloid leukemia41 (43)56 (100)97 (52) Myelodysplastic syndrome5 (5)5 (3) Acute lymphoblastic leukemia16 (17)12 (100)28 (15) Hodgkin lymphoma9 (9)2 (8)11 (6) Non-Hodgkin lymphoma9 (7)11 (46)20 (11) Chronic lymphoid leukemia1 (1)1 (1) Myeloma5 (5)9 (38)14 (7) Chronic myeloid leukemia3 (3)3 (2) Other6 (6)2 (8)10 (5)Disease status (relapse or refractory)56 (59)6 (11)4 (33)11 (46)77 (41)Underlying conditions Autologous transplant00015 (63)15 (8) Allogeneic transplant^a^95 (100)00095 (51) GVHD^b,c^27 (28)27 (28)  Grade I--II acute GVHD1010  Grade III--IV acute GVHD1414  Chronic GVHD77 Neutropenic phase^c^38 (40)38 (40) ANC \< 0.5, 10/l for at least 10 days16 (17)28 (50)6 (50)4 (17)54 (29) Persistent fever refractory to antibiotic therapy6 (6)7 (13)1 (8)1 (4)15 (8) Previous IFD19 (20)8 (14)2 (17)029 (16)Ongoing treatments Chemotherapy44 (46)49 (88)12 (100)8 (33)113 (60) Antibiotics80 (84)44 (79)11 (92)17 (71)152 (81) Immunosuppressants67 (71)3 (5)6 (50)2 (8)78 (42) Antivirals87 (92)39 (64)10 (83)20 (83)156 (83)Time since entry in the unit ≥ 30 days20 (21)33 (59)2 (17)1 (4)30 (16) Between 15 and 29 days14 (15)16 (29)3 (25)3 (13)36 (19) \< 15 days61 (64)7 (13)7 (58)20 (83)121 (65)Hospitalization in room with air treatment82 (86)48 (86)9 (75)18 (75)157 (84) Laminar air flow room or Immunair™ bed^d^60 (73)22 (46)2 (22)1 (6)85 (54) Highly purified HEPA-filtered room^d^18 (22)19 (40)4 (44)12 (67)53 (34) Conventional room with Plasmair™ or equivalent^d^4 (5)7 (14)3 (33)5 (28)19 (12)Data are *n* (%), unless otherwise specified*ANC* absolute neutrophil count*, GVHD* graft-versus-host disease, *IFD* invasive fungal disease^a^82 patients transplanted for less than 6 months^b^Chronic and/or acute GVHD^c^Percentage among recipients of allogeneic hematopoietic stem cell transplant^d^Percentage among patients hospitalized in a room with air treatment

Factors associated with prophylactic strategy were researched using a logistic regression model among the 246 treated patients. The results of univariate analysis are presented in Table [5](#Tab5){ref-type="table"}. Multivariate analysis showed that allogeneic HSCT (OR 4.57, 95% CI 2.47--8.47; *p *\< 0.0001), AML or MDS (OR 3.07, 95% CI 1.68--5.61; *p *\< 0.0001), antiviral treatment (OR 3.46, 95% CI 2.11--5.67; *p *\< 0.0001), and entry in a sterile room (OR 2.39, 95% CI 1.51--3.79; *p *\< 0.0002) were associated with systemic antifungal prophylaxis prescription.Table 5Factor associated with antifungal prophylactic strategy: univariate analysisNo antifungal prophylactic strategy\
*n *=307Antifungal prophylactic strategy\
*n *=187*p* value\*Pathology profile Group 152 (17)95 (51)\< 0.001 (S) Group 275 (24)56 (30) Group 359 (19)12 (6) Group 4121 (39)24 (13)Gender Male175 (57.)112 (60)0.528 (NS) Female132 (43)75 (40)Age group Pediatrics51 (17)13 (7)0.002 (S) Adults256 (83)174 (93)Entry in a sterile room^a^ No185 (60%)49 (6%)\< 0.001 (S) Yes122 (40%)138 (74%)First-line treatment No115 (38)75 (40)0.557 (NS) Yes192 (62)112 (60)Disease status Missing values22 Initial phase201 (66)108 (58)0.094 (NS) Relapse/refractory104 (34)77 (42)ANC \< 0.5, 10/l for at least 10 days Missing values10 No233 (76)133 (71)0.216 (NS) Yes73 (24)54 (29)Persistent fever refractory to antibiotherapy No272 (89)172 (92)0.227 (NS) Yes35 (11)15 (8)Previous IFD No274 (89)158 (85)0.121 (NS) Yes33 (11)29 (15)Ongoing chemotherapy No93 (30)74 (40)0.034 (S) Yes214 (70)113 (60)Ongoing antibiotherapy No90 (29)35 (19)0.009 (S) Yes217 (71)152 (81)Ongoing immunosuppressive treatment No224 (73)109 (58)0.001 (S) Yes83 (27)78 (42)Ongoing antiviral treatment No148 (48)31 (17)\< 0.001 (S) Yes159 (52)156 (83)Ongoing monoclonal antibody No288 (94)183 (98)0.038 (S) Yes19 (6)4 (2)Data are *n* (%)*ANC* absolute neutrophil count, *IFD* invasive fungal disease\*Pearson *χ*^2^ test (two sided)^a^Sterile room is defined as Laminar flow sterile room, Immunair™ bed, or highly purified HEPA-filtered room

Antifungal Drugs Prescribed {#Sec12}
---------------------------

Antifungal drugs prescribed to patients who received antifungal prophylactic strategy are presented in Table [6](#Tab6){ref-type="table"}. Overall, 79% of the patients who received antifungal prophylaxis during the 5-day observational period were administered an azole, 10% an intravenous amphotericin B formulation, 9% an echinocandin, and 2% a combination of two drugs. The most commonly used prophylactic drugs were fluconazole (administered to 41% of the patients who received prophylaxis), posaconazole (29%), amphotericin B (11%: liposomal 7%, conventional 4%), voriconazole (9%), caspofungin (7%), and micafungin (3%). Slight differences were observed when comparing the patients who received primary prophylaxis (*n *=145) to those who received secondary prophylaxis (*n *=42): posaconazole and fluconazole were administered to 73% of the patients receiving primary prophylaxis versus 60% of the patients receiving secondary prophylaxis, while voriconazole (either oral or intravenous) was administered to 4% of the patients receiving primary prophylaxis versus 24% of those receiving secondary prophylaxis (Table [7](#Tab7){ref-type="table"}).Table 6Systemic antifungal prophylactic strategy: drugs administered according to the pathology profileGroup 1\
*n *= 95Group 2\
*n *= 56Group 3\
*n *= 12Group 4\
*n *= 24Total\
*n *= 187Missing values1 (1)0001 (0.5)Azole alone70 (74)49 (88)7 (58)22 (92)148 (79)Amphotericin B formulation alone10 (11)5 (9)2 (17)1 (4)18 (10)Echinocandin alone13 (14)1 (2)2 (17)1 (4)17 (9)Amphotericin B formulation and azole1 (1)1 (2)002 (1)Amphotericin B formulation and echinocandin001 (8)01 (0.5)Azole type *N*7150722150 PO fluconazole38 (54)5 (10)4 (57)16 (73)63 (42) IV fluconazole6 (8)3 (6)04 (18)13 (9) PO posaconazole16 (23)35 (70)3 (43)1 (5)55 (37) PO voriconazole8 (11)4 (8)0012 (8) IV voriconazole3 (4)1 (2)004 (3) Itraconazole01 (2)01 (5)2 (1) Posaconazole---PO voriconazole01 (2)001 (1)Amphotericin B formulation *N*1163121 IV liposomal amphotericin B8 (73)4 (67)2 (67)014 (67) IV conventional amphotericin B3 (27)2 (33)1 (33)1 (100)7 (33)Echinocandin type *N*1313118 Caspofungin11 (85)1 (100)1 (33)013 (72) Micafungin2 (15)02 (67)1 (100)5 (28)Data are *n* (%) Table 7Systemic antifungal drugs prescribed according to the type of prophylactic strategyPrimary prophylaxis\
*n *=145Secondary prophylaxis\
*n *=42Total\
*n *= 187Missing values1 (1)01 (0.5)Amphotericin B formulation alone111 (77)37 (88)148 (79)Amphotericin B alone15 (10)3 (7)18 (10)Echinocandin alone15 (10)2 (5)17 (9)Amphoterin B formulation and azole2 (1)02 (1)Amphotericin B formulation and echinocandin1 (1)01 (0.5)Azole type *n*11337150 PO fluconazole50 (44)13 (35)63 (42) IV fluconazole12 (11)1 (3)13 (9) PO posaconazole44 (39)11 (30)55 (37) PO voriconazole4 (4)8 (22)12 (8) IV voriconazole2 (2)2 (5)4 (3) Itraconazole1 (1)1 (3)2 (1) Posaconazole---PO voriconazole01 (3)1 (1)Amphotericin B formulation *n*18321 IV liposomal amphotericin B11 (61)3 (100)14 (67) IV conventional amphotericin B7 (39)07 (33)Echinocandin type *n*16218 Caspofungin12 (75)1 (50)13 (72) Micafungin4 (25)1 (50)5 (28)Data are *n* (%)

Discussion {#Sec13}
==========

The AFHEM study was the first cross-sectional observational study to determine the use of antifungal treatment strategies used in hematologic patients in medical practice in France. Half of the patients hospitalized in hematology centers received a systemic antifungal agent (53% in adults and 31% in pediatric patients), and prophylaxis was the leading strategy used.

Guidelines and expert committees suggest risk stratifying patients from very low risk to very high risk of developing IFD to determine the most appropriate antifungal strategy \[[@CR6], [@CR11], [@CR21]\]. Unfortunately, there is no uniformity across the guidelines for the criteria for each group. In this study, the proportion of patients receiving systemic antifungal prophylaxis ranged from 17% to 65% of the whole population and from 63% to 80% of patients treated with antifungals, depending on the risk level for IFD. Interestingly, 81% of patients who received prophylaxis were either allogeneic HSCT patients or AML patients, and these indications are therefore in accordance with international recommendations.

Azoles are recommended for prophylaxis in high-risk patients \[[@CR5], [@CR6], [@CR9]--[@CR11]\]. Guidelines from ECIL \[[@CR6]\] and the German Society for Hematology and Medical Oncology \[[@CR22]\] recommend that the choice of antifungal agent is based on clinical indication. For example, during the neutropenic phase following an allogeneic transplant, fluconazole is recommended for patients at low risk of developing invasive aspergillosis, but this is to be switched in patients at high risk of invasive aspergillosis (to voriconazole) or if patients develop GVHD (to posaconazole). We found that oral or intravenous fluconazole was the predominant drug used during the neutropenic phase in HSCT patients to prevent invasive candidiasis combined with sterile air conditions in to prevent IFD due to filamentous fungi, as mentioned above. Of note, if fluconazole is chosen, there is also a need for a mold-directed diagnostic strategy \[[@CR7]\]. Consistent with recommendations for patients with AML or MDS receiving intensive chemotherapy, we found that posaconazole was the main drug (63%) used in this group of patients. The ECIL-3 guidelines also recommend voriconazole for both the neutropenic and GVHD phases in allogeneic HSCT settings. In our study, voriconazole was only rarely prescribed for prophylaxis, except in cases of secondary prophylaxis.

A French case-control study previously published in 2011 showed a significant association between prior exposure to caspofungin and an elevated risk of bloodstream infection caused by *Candida* spp. having reduced susceptibility to caspofungin in adults with hematologic malignancies \[[@CR23]\]. Thus, considering these results and those published on azole resistance, use of antifungal medications always requires constant vigilance for resistance emergence, particularly during long-term prophylaxis.

Eighty-four percent of the patients receiving antifungal prophylaxis were hospitalized in rooms with air treatment, 88% of them being placed in a sterile room (in a laminar air flow room, Immunair™ bed, or highly purified HEPA-filtered room), thus combining drug administration with environmental measures to prevent systemic infections and illustrating the appropriate perception of high-risk conditions by the clinicians. The low rate of empiric, preemptive, and curative therapies in groups 1 and 2 (20% and 28%, respectively) might be explained by the high level and rate of prophylactic strategies. Of note, empiric therapy is used more often in children (25%) than in adults (9%).

Although providing interesting information on patients receiving antifungal prophylaxis in French hematology units, our study has some limitations, mainly due to its design. First, we can assume that physician selection bias could also have led to patient selection bias. Indeed, physician participation was offered on a voluntary basis, and the final center sample may not be representative of the use of antifungal therapy in France. This potential bias is inevitable in this type of study, and its impact is difficult to evaluate. Moreover, even though the sample was comprehensive, the patients could refuse to participate in the study, and the final population may not be perfectly representative. To be included in the study, the patients (or their representative) were required to give their written approval. We established a registry to record the patients hospitalized in participating units and eligible for the study. Of the 158 patients recorded in the registry who did not give their written approval for participation in the study (25%), 128 did not receive any antifungal drug. It can thus be assumed that the proportion of patients treated with a systemic antifungal drug could have been slightly overestimated.

Conclusion {#Sec14}
==========

This work provides a comprehensive picture of patients hospitalized in French hematology units and treated with antifungal prophylaxis. Prophylaxis is now the leading strategy used in hematology, whatever the disease conditions of the patients with overall 76% of patients managed in this way. Prophylaxis is mainly based on fluconazole and posaconazole. Fluconazole is still used in allogeneic HSCT patients, in most cases associated with protected environmental conditions. Posaconazole is mainly used in AML/MDS patients, but also in ALL patients where its use is off-label. Echinocandins are mainly used in high-risk patients, and caspofungin is the most used echinocandin, although it is not licensed for prophylaxis. Antifungal stewardship programs are thus of prime interest to rationalize antifungal use \[[@CR24]\]. As recently published \[[@CR25]\], although neutropenia is common to almost all hematologic patients, other factors (low complete response probability due to an adverse karyotype in AML, high-dose dexametazone in ALL, allogeneic HSCT from donors other than a matched sibling donor) may play a key role in these patients and may help to design the most appropriate diagnostic workup and antifungal strategy.
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